针对hERG1和β1整合素复合体进行癌症治疗
Annarosa Arcangeli1,2,3, Jessica Iorio1, Claudia Duranti1,3
1Department of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Firenze, Italy.
Expert opinion on therapeutic targets
|February 19, 2024
概括
针对hERG1/β1整体综合体的新型双特异性抗体为抗瘤疗法提供了一个有前途的战略. 这种方法克服了与传统hERG1抑制剂相关的心脏毒性,在临床前癌症模型中显示出潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 新型治疗策略对于转移性癌瘤至关重要,包括乳腺癌,结直肠癌,胰腺癌和癌.
- 离子通道,特别是hERG1通道,正在成为重要的癌症生物标志物和治疗点.
- 在人类的侵略性癌症中观察到hERG1的异常表达.
研究的目的:
- 研究hERG1通道作为抗瘤治疗的新目标.
- 开发一个有针对性的治疗策略,克服传统的hERG1封锁的局限性.
- 评估一种针对hERG1/β1整合素复合体的新型双特异性抗体的抗性作用.
主要方法:
- 鉴定癌细胞中独特的hERG1构造,特别是其与β1整蛋白子单元的复合物.
- 开发一种单链双特异性抗体 (scDb-hERG1-β1),旨在向hERG1/β1整合素复合体.
- 在临床前评估scDb-hERG1-β1抗体的抗瘤疗效.
主要成果:
- 在癌细胞中,hERG1/β1整合素复合体是唯一存在的,而不是在心脏组织中.
- 开发的双特异性抗体scDb-hERG1-β1特别针对hERG1/β1整合素复合体.
- 临床前实验表明,scDb-hERG1-β1抗体介导的抗瘤作用.
结论:
- 向hERG1/β1整合素复合体是专门针对癌症中的hERG1的可行策略.
- 双特异性抗体scDb-hERG1-β1提供了一个潜在的解决方案,以规避与一般hERG1抑制剂相关的心脏毒性.
- 这种有针对性的方法对开发用于各种癌症的新型抗瘤疗法充满希望.
关键词:
双特异性抗体 双特异性抗体在KCNH2中,KCNH2是11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1 Kv 11.1癌症的信号传递.癌症治疗 治疗 治疗 癌症离子通道 离子通道转移 转移 转移 转移治疗性抗体治疗性抗体.更多相关视频
06:27A 3D Spheroid Model as a More Physiological System for Cancer-Associated Fibroblasts Differentiation and Invasion In Vitro Studies
Published on: August 8, 2019
8.9K
04:15Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
Published on: February 2, 2024
1.8K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Activation of Integrins
3.4K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
3.4K
Intracellular Signaling Affects Focal Adhesions
2.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.7K
Integrins
4.0K
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
4.0K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Selectins
3.3K
Cell adhesion is an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.3K
